Cognitive functions in low-grade gliomas: disease and treatment effects

J Neurooncol. 2007 Jan;81(2):175-84. doi: 10.1007/s11060-006-9212-3. Epub 2006 Jul 19.

Abstract

Background: The role of radiotherapy and chemotherapy in the treatment of low-grade gliomas (LGG) is controversial regarding their effect on survival and the development of neurotoxicity. The few published studies examining adverse treatment effects on cognition revealed conflicting results.

Objective: To assess cognitive functioning in LGG patients who received conformal radiation therapy (RT), chemotherapy, or no treatment.

Design: 40 LGG patients participated in the study; 16 patients had RT +/- chemotherapy, and 24 patients had no treatment. All patients underwent a neuropsychological evaluation. APOE genotype was obtained in 36 patients who were classified in two groups based on the presence or absence of at least one apolipoprotein E small je, Ukrainian-4 (APOE small je, Ukrainian-4) allele.

Results: Treated LGG patients had lower scores than untreated patients on several cognitive domains; patients who completed treatment at intervals greater than 3 years and had long disease duration had significantly lower scores on the Non-Verbal Memory domain. Antiepileptic polytherapy, treatment history, and disease duration jointly contributed to low Psychomotor domain scores. 62% of treated patients showed white matter confluence on MRI, whereas only 9% of the untreated patients had such changes. Preliminary comparisons between APOE small je, Ukrainian-4 carriers (n = 9) and non-carriers (n = 27) on cognitive domain scores revealed no statistically significant differences, but APOE small je, Ukrainian-4 carriers had lower mean scores on the Verbal Memory domain than did non-small je, Ukrainian-4 carriers.

Conclusions: RT +/- chemotherapy, disease duration, and antiepileptic treatment contributed to mild cognitive difficulties in LGG patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antineoplastic Agents / therapeutic use
  • Apolipoprotein E4 / genetics
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / physiopathology*
  • Brain Neoplasms / radiotherapy
  • Cognition Disorders / physiopathology*
  • Epilepsy / etiology
  • Epilepsy / therapy
  • Female
  • Glioma / drug therapy
  • Glioma / physiopathology*
  • Glioma / radiotherapy
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests

Substances

  • Antineoplastic Agents
  • Apolipoprotein E4